DE602004015272D1 - Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase - Google Patents

Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase

Info

Publication number
DE602004015272D1
DE602004015272D1 DE602004015272T DE602004015272T DE602004015272D1 DE 602004015272 D1 DE602004015272 D1 DE 602004015272D1 DE 602004015272 T DE602004015272 T DE 602004015272T DE 602004015272 T DE602004015272 T DE 602004015272T DE 602004015272 D1 DE602004015272 D1 DE 602004015272D1
Authority
DE
Germany
Prior art keywords
hyperactive
bubble
treatment
acid derivatives
phenoxy acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004015272T
Other languages
English (en)
Inventor
Yoshinobu Yamazaki
Masami Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004015272(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10320084A external-priority patent/DE10320084A1/de
Priority claimed from DE2003123837 external-priority patent/DE10323837A1/de
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of DE602004015272D1 publication Critical patent/DE602004015272D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004015272T 2003-05-05 2004-03-24 Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase Expired - Lifetime DE602004015272D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10320084A DE10320084A1 (de) 2003-05-05 2003-05-05 Verwendung von Phenoxyessigsäurederivaten zur Behandlung der hyperaktiven Blase
DE2003123837 DE10323837A1 (de) 2003-05-23 2003-05-23 Verwendung von Phenoxyessigsäurederivaten zur Behandlung der hyperaktiven Blase
PCT/JP2004/004048 WO2004098586A1 (en) 2003-05-05 2004-03-24 Use of phenoxyacetic acid derivatives for treating hyperactive bladder

Publications (1)

Publication Number Publication Date
DE602004015272D1 true DE602004015272D1 (de) 2008-09-04

Family

ID=33420009

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004015272T Expired - Lifetime DE602004015272D1 (de) 2003-05-05 2004-03-24 Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase

Country Status (26)

Country Link
US (1) US20040229947A1 (de)
EP (1) EP1620085B1 (de)
JP (1) JP4602969B2 (de)
KR (1) KR101052804B1 (de)
AR (1) AR044169A1 (de)
AT (1) ATE401878T1 (de)
AU (1) AU2004236596B2 (de)
BR (1) BRPI0409980A (de)
CA (1) CA2524023C (de)
CL (1) CL2004000952A1 (de)
CY (1) CY1108425T1 (de)
DE (1) DE602004015272D1 (de)
DK (1) DK1620085T3 (de)
ES (1) ES2309513T3 (de)
IL (1) IL171713A (de)
MX (1) MXPA05011862A (de)
MY (1) MY141756A (de)
NZ (1) NZ543347A (de)
PE (1) PE20050524A1 (de)
PL (1) PL1620085T3 (de)
PT (1) PT1620085E (de)
RU (1) RU2342133C2 (de)
SI (1) SI1620085T1 (de)
TW (1) TWI351279B (de)
UY (1) UY28306A1 (de)
WO (1) WO2004098586A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI356699B (en) 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
CA2605298A1 (en) * 2005-04-26 2006-11-09 Kissei Pharmaceutical Co., Ltd. Crystal of hydroxynorephedrin derivative hydrochloride 1/4 hydrate
US7763654B2 (en) * 2005-04-26 2010-07-27 Kissei Pharmaceutical Co., Ltd. Crystal polymorph of hydroxynorephedrin derivative hydrochloride
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6720014B1 (en) * 1997-08-13 2004-04-13 Diversa Corporation Phytase-containing foodstuffs and methods of making and using them
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
DE60041110D1 (de) * 1999-11-01 2009-01-29 Sumitomo Chemical Co 6-Hydroxy-5,6-dihydrouracile als Herbizide
CA2458544C (en) * 2001-09-13 2010-08-17 Kissei Pharmaceutical Co., Ltd. Crystals of hydroxynorephedrine derivative

Also Published As

Publication number Publication date
AR044169A1 (es) 2005-08-24
DK1620085T3 (da) 2008-11-24
PL1620085T3 (pl) 2009-01-30
PE20050524A1 (es) 2005-07-07
NZ543347A (en) 2008-05-30
CY1108425T1 (el) 2014-04-09
IL171713A (en) 2011-12-29
MY141756A (en) 2010-06-30
CA2524023C (en) 2011-11-22
PT1620085E (pt) 2008-08-07
BRPI0409980A (pt) 2006-05-09
KR20060009886A (ko) 2006-02-01
TWI351279B (en) 2011-11-01
AU2004236596B2 (en) 2010-03-11
SI1620085T1 (sl) 2008-12-31
KR101052804B1 (ko) 2011-07-29
RU2005137701A (ru) 2006-06-10
CL2004000952A1 (es) 2005-03-04
RU2342133C2 (ru) 2008-12-27
EP1620085B1 (de) 2008-07-23
AU2004236596A1 (en) 2004-11-18
MXPA05011862A (es) 2006-02-17
EP1620085A1 (de) 2006-02-01
CA2524023A1 (en) 2004-11-18
JP4602969B2 (ja) 2010-12-22
TW200509902A (en) 2005-03-16
ES2309513T3 (es) 2008-12-16
US20040229947A1 (en) 2004-11-18
ATE401878T1 (de) 2008-08-15
UY28306A1 (es) 2004-12-31
JP2006525318A (ja) 2006-11-09
WO2004098586A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602005002930D1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE602005027388D1 (de) Malonsäureamidderivate als inhibitoren von g-sekretase zur behandlung von alzheimer-krankheit
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE439347T1 (de) 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DE60309719D1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: WESTENDORP SOMMER, 80336 MUENCHEN